抗肥胖药物开发商Metsera美股盘前涨幅进一步至50%

Core Insights - Metsera, a developer of anti-obesity drugs, saw its stock price increase by 50% in pre-market trading on September 22 [1] Company Summary - Metsera is focused on the development of anti-obesity medications, indicating a strong market interest and potential for growth in this sector [1]